Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E15.90 EPS (ttm)12.63 Insider Own0.20% Shs Outstand607.00M Perf Week2.66%
Market Cap121.89B Forward P/E12.65 EPS next Y15.87 Insider Trans-2.09% Shs Float598.41M Perf Month3.51%
Income7.96B PEG2.05 EPS next Q3.50 Inst Own79.40% Short Float1.43% Perf Quarter14.01%
Sales23.56B P/S5.17 EPS this Y14.80% Inst Trans0.18% Short Ratio2.83 Perf Half Y4.90%
Book/sh17.78 P/B11.29 EPS next Y10.53% ROA12.40% Target Price214.84 Perf Year-0.20%
Cash/sh35.85 P/C5.60 EPS next 5Y7.77% ROE65.70% 52W Range166.30 - 211.90 Perf YTD3.15%
Dividend5.80 P/FCF21.77 EPS past 5Y13.70% ROI19.80% 52W High-5.24% Beta1.07
Dividend %2.89% Quick Ratio2.60 Sales past 5Y4.90% Gross Margin82.20% 52W Low20.75% ATR3.68
Employees21500 Current Ratio2.90 Sales Q/Q-3.10% Oper. Margin41.80% RSI (14)58.91 Volatility1.67% 1.66%
OptionableYes Debt/Eq2.84 EPS Q/Q2.70% Profit Margin33.80% Rel Volume0.81 Prev Close198.68
ShortableYes LT Debt/Eq2.58 EarningsOct 29 AMC Payout43.60% Avg Volume3.02M Price200.80
Recom2.30 SMA202.78% SMA501.49% SMA2006.99% Volume2,477,386 Change1.07%
Aug-19-19Downgrade Mizuho Buy → Neutral $208 → $212
May-23-19Upgrade Citigroup Neutral → Buy
May-21-19Initiated Credit Suisse Outperform $208
Jan-28-19Downgrade Evercore ISI Outperform → In-line
Oct-01-18Initiated Cantor Fitzgerald Neutral $223
Apr-05-18Reiterated Barclays Equal Weight $190 → $180
Feb-12-18Reiterated Mizuho Buy $192 → $200
Jan-23-18Upgrade Argus Hold → Buy
Nov-01-17Downgrade Argus Buy → Hold
Oct-26-17Reiterated RBC Capital Mkts Sector Perform $192 → $188
Sep-28-17Reiterated Mizuho Buy $183 → $198
Sep-15-17Initiated RBC Capital Mkts Sector Perform $192
Jul-11-17Resumed Jefferies Buy
Jun-23-17Initiated Deutsche Bank Hold $172
Apr-05-17Downgrade Jefferies Buy → Hold
Mar-09-17Initiated UBS Neutral $185
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Oct-12-19 12:26PM  These battered biotech stocks are now buying opportunities as Elizabeth Warren climbs in the polls MarketWatch
Oct-11-19 04:27PM  Here Are Two Biotech Stocks To Watch As Earnings Season Kicks Off Investor's Business Daily
12:29PM  Top Research Reports for Toyota, Amgen & TJX Zacks
09:27AM  Alexion (ALXN) Collaborates With Stealth BioTherapeutics Zacks
Oct-10-19 10:58AM  3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates Zacks
07:03AM  Should You Be Worried About Insider Transactions At Amgen Inc. (NASDAQ:AMGN)? Simply Wall St.
Oct-09-19 05:45PM  Amgen (AMGN) Gains But Lags Market: What You Should Know Zacks
04:46PM  Is Amgen, Inc. (AMGN) A Good Stock To Buy According To Hedge Funds? Insider Monkey
09:04AM  Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh PR Newswire
Oct-08-19 03:10PM  Phillips 66 puts former Walmart CFO on board American City Business Journals
11:43AM  UPDATE 2-Humira, Rituxan top list of U.S. drugs with biggest price increases -report Reuters
09:18AM  Why Alexion is a Hot Takeover Target in the Biotech Sector Zacks
Oct-07-19 10:36AM  Pfenex Gets FDA Seal of Approval For Amgen's Forteo Biosimilar Benzinga
09:30AM  Has Amgen (AMGN) Outpaced Other Medical Stocks This Year? Zacks
06:00AM  After 500% Surge, Miratis Day of Reckoning Is Approaching Bloomberg
Oct-04-19 04:29PM  A Key Novartis Drug Could Be Delayed Why This Stock Is Cheering Investor's Business Daily
12:00PM  Why This Biotech Stock Is Cheering A Potential Novartis Biosimilar Delay Investor's Business Daily
09:30AM  3 Drug Stocks Poised for Gains After Cancer Conference Investopedia
08:00AM  Amgen Stock Is The Biggest Biotech Stock, But Should You Buy It? Investor's Business Daily
Oct-03-19 05:45PM  Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know Zacks
03:49PM  Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar Benzinga
11:22AM  Merck's Pediatric Filings for Dificid Get FDA's Priority Review Zacks
07:00AM  Amgen, Merck and Others Highlighted Cancer-Drug Developments in Barcelona Barrons.com
Oct-02-19 11:04AM  Seeing the Baseline GuruFocus.com
10:10AM  Why the Earnings Surprise Streak Could Continue for Amgen (AMGN) Zacks
07:34AM  Top Ranked Income Stocks to Buy for October 2nd Zacks
Oct-01-19 09:10AM  Should Value Investors Buy Amgen (AMGN) Stock? Zacks
08:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
Sep-30-19 02:07PM  Seattle Genetics, Merck, Bristol-Myers Unveil Upbeat Treatment Data at Cancer Conference Barrons.com
Sep-28-19 11:02AM  Bye-bye, Biotech Funds? Not So Fast. It Could Be Time for Another Look Barrons.com
10:59AM  UPDATE 1-Targeted Amgen drug has low response rate in colon cancer in study Reuters
01:30AM  Low response rate reported for Amgen targeted drug in colon cancer trial Reuters
01:00AM  Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019 PR Newswire
Sep-27-19 05:50PM  Amgen (AMGN) Stock Moves -0.23%: What You Should Know Zacks
09:34AM  Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar? Zacks
09:15AM  ARWR: Broad-Based Pipeline Progress. Three Pivotal Studies, Value-Inflection Opportunities In View. Zacks Small Cap Research
Sep-26-19 04:55PM  Cutting Rates 50 bps. Smart, Dumb, Not Enough? Zacks
12:05PM  Medicines Company's Inclisiran Succeeds in Pivotal Studies Zacks
10:46AM  A Big Cancer Conference Starts Tomorrow. Heres What It Means for Merck, Bristol-Myers and Other Drug Stocks. Barrons.com
09:02AM  Incyte Treats First Patient in Phase III Vitiligo Study Zacks
09:00AM  Heart Attack Survivors Are Taking Steps To Reduce Their Cardiovascular Risk. But Are They The Right Ones? PR Newswire
Sep-25-19 04:37PM  How This IBD Stock Of The Day Is Rattling Medical Giants Amgen, Mylan Investor's Business Daily
04:00PM  Amgen To Webcast Investor Call At ESMO 2019 PR Newswire
11:10AM  Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More Zacks
07:13AM  The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug Benzinga
Sep-24-19 04:00PM  Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia PR Newswire
Sep-23-19 12:08PM  Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent Zacks
Sep-22-19 01:33PM  Amgen Looks Attractive After Its Recent Pullback TheStreet.com
Sep-20-19 05:50PM  Amgen (AMGN) Gains As Market Dips: What You Should Know Zacks
04:29PM  5 Safe Bets for a Rocky Market Zacks
11:21AM  Amgen, Walt Disney, Microsoft, Apple and Oracle highlighted as Zacks Bull and Bear of the Day Zacks
08:31AM  3 Big Biotech Stocks Worth Adding to Your Portfolio Now Zacks
06:45AM  Bull of the Day: Amgen (AMGN) Zacks
Sep-19-19 07:38AM  Read This Before You Buy Amgen Inc. (NASDAQ:AMGN) Because Of Its P/E Ratio Simply Wall St.
07:17AM  Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019 Zacks
Sep-18-19 10:41AM  Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma Zacks
10:33AM  Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More Zacks
Sep-17-19 04:00PM  Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019 PR Newswire
10:44AM  Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review Zacks
09:58AM  The Zacks Analyst Blog Highlights: Amgen, Tokyo Electron and Kinross Gold Zacks
09:26AM  Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck Zacks
Sep-16-19 03:38PM  Top Stock Picks for Week of September 16, 2019 Zacks
01:18PM  Aimmune's Peanut Allergy Drug Gets FDA Committee's Support Zacks
11:30AM  S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels PR Newswire
08:48AM  Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study Zacks
Sep-13-19 04:00PM  Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference PR Newswire
11:08AM  Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland Zacks
10:30AM  Celgene's (CELG) Leukemia Candidate Meets Endpoints in Study Zacks
10:13AM  The Zacks Analyst Blog Highlights: Amgen, Cisco, Berkshire Hathaway, T. Rowe Price and McKesson Zacks
09:00AM  Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival PR Newswire
08:44AM  REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8% Zacks
05:00AM  2019 BusinessWoman of the Year honoree: Jaclyn Schuler American City Business Journals
Sep-12-19 01:52PM  Top Research Reports for Amgen, Cisco & Berkshire Hathaway Zacks
10:13AM  Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance Zacks
09:00AM  Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019 PR Newswire
Sep-11-19 11:49AM  deCODE in Iceland Agrees to Sequence Half of UK Biobanks Participants CNW Group
11:37AM  Ultragenyx to Submit sBLA for Label Expansion of Crysvita Zacks
10:49AM  Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus Zacks
Sep-10-19 04:13PM  Is Nancy Pelosi's Drug-Pricing Plan Feasible Or Is It A Political Ploy? Investor's Business Daily
11:39AM  Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan Zacks
09:31AM  Company News For Sep 10, 2019 Zacks
09:01AM  Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy Zacks
07:59AM  Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review Zacks
06:55AM  Amgen Falls 3% Investing.com
Sep-09-19 04:24PM  Amgen Stock Dives On Lackluster Cancer Test But There's A Bright Side Investor's Business Daily
01:38PM  US STOCKS-Tech, healthcare weigh on Wall Street, stimulus hopes flicker Reuters
12:17PM  [video]Dow Finishes Higher; Wall Street Wavers Amid Expected Central Bank Stimulus TheStreet.com
11:21AM  Novartis Announces Positive Long-Term Data on Migraine Drug Zacks
10:27AM  Amgen's KRAS Inhibitor Shows Lukewarm Response In Lung Cancer Study Benzinga
10:26AM  [video]Eli Lilly's Must-Hold Level on Drug-Data Pullback TheStreet.com
10:10AM  Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group Zacks
08:59AM  Amgen Stock Is Falling as Cancer-Drug Report Fails to Impress Investors Barrons.com
08:17AM  Could Small Drug Trial Hold Big Potential for Amgen? TheStreet.com
06:22AM  [video]Amgen Shares Tumble After Lung Cancer Treatment Update Misses Forecasts TheStreet.com
05:41AM  Amgen's Lower Open Tests Support but the Bigger Picture Is More Important TheStreet.com
05:34AM  Amgen Falls 3% Investing.com
Sep-08-19 11:07PM  Amgen/cancer drugs: Seal of approval Financial Times
09:00AM  Better Buy: Amgen vs. Celgene Motley Fool
03:45AM  Amgen drug shrinks lung cancer tumors in half of patients -study Reuters
03:45AM  Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019 PR Newswire
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; Syapse; and DaVita Inc., as well as strategic research partnership with the University of Washington's Institute for Protein Design. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUGAR RONALD DDirectorOct 02Option Exercise54.712,000109,42016,436Oct 03 05:06 PM
SUGAR RONALD DDirectorOct 02Sale193.582,000387,16014,436Oct 03 05:06 PM
SUGAR RONALD DDirectorSep 04Option Exercise54.712,000109,42016,336Sep 04 06:08 PM
SUGAR RONALD DDirectorSep 04Sale206.702,000413,40014,336Sep 04 06:08 PM
Patton Cynthia MSVP & CCOAug 30Option Exercise158.438,6241,366,33132,648Sep 04 06:07 PM
Patton Cynthia MSVP & CCOAug 30Sale208.0713,4262,793,51022,097Sep 04 06:07 PM
SUGAR RONALD DDirectorAug 07Option Exercise54.712,000109,42016,336Aug 08 07:09 PM
Williams R SandersDirectorAug 07Sale183.0442577,7925,838Aug 08 07:12 PM
SUGAR RONALD DDirectorAug 07Sale183.042,000366,08014,336Aug 08 07:09 PM
SUGAR RONALD DDirectorJul 03Option Exercise54.712,000109,42016,336Jul 08 04:23 PM
SUGAR RONALD DDirectorJul 03Sale187.582,000375,16014,336Jul 08 04:23 PM
SUGAR RONALD DDirectorJun 05Option Exercise54.712,000109,42016,219Jun 05 06:55 PM
SUGAR RONALD DDirectorJun 05Sale175.682,000351,36014,219Jun 05 06:55 PM
SUGAR RONALD DDirectorMay 01Option Exercise54.712,000109,42015,092May 03 05:37 PM
SUGAR RONALD DDirectorMay 01Sale175.732,000351,46013,092May 03 05:37 PM
SUGAR RONALD DDirectorApr 03Option Exercise54.712,000109,42015,092Apr 03 06:27 PM
SUGAR RONALD DDirectorApr 03Sale193.182,000386,36013,092Apr 03 06:27 PM
SUGAR RONALD DDirectorMar 06Option Exercise54.712,000109,42014,988Mar 08 07:47 PM
SUGAR RONALD DDirectorMar 06Sale188.882,000377,76012,988Mar 08 07:47 PM
SUGAR RONALD DDirectorFeb 07Option Exercise54.712,000109,42014,988Feb 11 09:27 PM
SUGAR RONALD DDirectorFeb 07Sale190.002,000380,00012,988Feb 11 09:27 PM
Jacks TylerDirectorDec 06Option Exercise82.6020,0001,652,00028,979Dec 10 08:46 PM
Jacks TylerDirectorDec 06Sale195.4120,0003,908,2328,979Dec 10 08:46 PM
Piacquad DavidSVP, Business DevelopmentNov 30Option Exercise54.696,500355,48545,128Dec 03 08:13 PM
Patton Cynthia MSVP & CCONov 29Option Exercise54.691,77797,18423,090Dec 03 08:11 PM
Patton Cynthia MSVP & CCONov 29Sale202.881,777360,52021,313Dec 03 08:11 PM